Key facts
- Gate Bioscience’s last known valuation is $161.0M (Nov 2025).
- It has raised $134.5M; the latest was Early Stage VC ($65.0M) in Nov 2025.
- Notable investors include Andreessen Horowitz, GV, ARCH Venture Partners, Forbion, Versant Ventures — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Gate Bioscience
- ·The full record, as it builds
Funding rounds
No funding rounds for Gate Bioscience are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Gate Bioscience
Developer of small molecule drugs designed to selectively eliminate harmful extracellular proteins at their origin, inside cells, and prevent them from emerging to cause disease. The company combines a privileged library of molecular gates, a suite of bespoke secretion-focused assays and technologies, and expertise in the biology of the secretory pathway to enable precise, rapid, and repeatable drug development, enabling doctors to address a wide range of diseases with a single therapeutic mechanism.
- Sector
- Healthcare
- HQ
- Brisbane, CA, United States
- Founded
- 2021
- Employees
- 42
- Website
- gatebio.com/
- Ownership
- Privately Held (backing)
Gate Bioscience doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Gate Bioscience shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Gate Bioscience in its N-PORT filings yet. We sweep new filings monthly.